CRTH-2/GPR44 Antibody [Janelia Fluor® 635]
Novus Biologicals, part of Bio-Techne | Catalog # NB100-93564JF635
Conjugate
Catalog #
Forumulation
Catalog #
Key Product Details
Species Reactivity
Validated:
Human
Applications
Western Blot
Label
Janelia Fluor 635
Antibody Source
Polyclonal Rabbit IgG
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Summary for CRTH-2/GPR44 Antibody [Janelia Fluor® 635]
Immunogen
Synthetic peptide corresponding to residues 329-348 [DDSELGGAGSSRRRRTSSTA] of the CRTH2 (GPR44) protein.
Reactivity Notes
This antibody is reactive against Human
Specificity
CRTH2
Clonality
Polyclonal
Host
Rabbit
Isotype
IgG
Applications for CRTH-2/GPR44 Antibody [Janelia Fluor® 635]
Application
Recommended Usage
Western Blot
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Immunogen affinity purified
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: CRTH-2
Long Name
Chemoattractant Receptor-homologous Molecule Expressed on Th2 Cells
Alternate Names
CD294, CRTH2, GPR44, PGD2R, PTGDR2
Gene Symbol
PTGDR2
Additional CRTH-2 Products
Product Documents for CRTH-2/GPR44 Antibody [Janelia Fluor® 635]
Product Specific Notices for CRTH-2/GPR44 Antibody [Janelia Fluor® 635]
Sold under license from the Howard Hughes Medical Institute, Janelia Research Campus.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...